Amicus Therapeutics Inc
NASDAQ:FOLD
Amicus Therapeutics Inc
Total Equity
Amicus Therapeutics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
Total Equity
$178.8m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
15%
|
||
Abbvie Inc
NYSE:ABBV
|
Total Equity
$6B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$18.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
||
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$7.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-11%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$15.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$29.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
Amicus Therapeutics Inc
Glance View
In the ever-evolving landscape of biotech, Amicus Therapeutics Inc. stands as a beacon of innovation, rooted deeply in the realm of rare and orphan diseases. Founded with the mission to harness advanced therapies for conditions with limited treatment options, the company has carved a niche in developing treatments that hinge on cutting-edge science. Specifically, Amicus focuses on creating next-generation therapies involving chaperone proteins and genetic medicines. These specialized therapies work by stabilizing and enhancing the function of faulty proteins that are hallmarks of many genetic disorders, thereby directly addressing the underlying causes of these conditions. Their portfolio, prominently featuring Galafold (migalastat) for Fabry disease, exemplifies their approach—leveraging precision medicine to cater to patients who have been underserved by traditional pharmaceutical models. Revenue generation for Amicus Therapeutics predominantly revolves around the commercialization of Galafold, which is approved in numerous global markets. Galafold offers a personalized approach, being targeted towards individuals with Fabry disease who possess amenable genetic mutations. This specificity not only underscores Amicus's commitment to precision therapeutics but also reinforces its competitive edge, as the treatment reduces the necessity for enzymatic replacement, a conventional route with broader systemic impacts. Beyond its current offerings, Amicus is strategically investing in its pipeline of gene therapies, aiming to provide breakthroughs in conditions like Pompe disease and other rare metabolic disorders. By enhancing existing therapies and fostering new breakthroughs, Amicus not only upholds its commitment to patient-centric solutions but also bolsters its financial sustainability through strategic innovation and market expansion.
See Also
What is Amicus Therapeutics Inc's Total Equity?
Total Equity
178.8m
USD
Based on the financial report for Sep 30, 2024, Amicus Therapeutics Inc's Total Equity amounts to 178.8m USD.
What is Amicus Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
15%
Over the last year, the Total Equity growth was 34%. The average annual Total Equity growth rates for Amicus Therapeutics Inc have been -22% over the past three years , -20% over the past five years , and 15% over the past ten years .